Poster: AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览19

暂无评分

摘要

SEL24/MEN1703 had a manageable safety profile and single-agent activity in adult patients with R/R IDHm AML and may be a feasible therapeutic option in this difficult-to-treat population.

查看译文

关键词

AML,acute myeloid leukemia,FLT3-ITD, FLT3 inhibitor,IDH mutation,PIM kinase,Trial-in-Progress

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要